Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid and Radiotherapy for NSCLC Bone Metastasis
NCT02480634Phase 4Unknown
- Start
- Jun 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in non-small cell lung cancer (NSCLC) and bone metastasis (2 arms). Primary endpoint: Percentage of Participants reach objective response at 1 month. Status: unknown.
02
Drugs
zoledronic acid
03
Conditions
non-small cell lung cancer (NSCLC)bone metastasis
Beyond the preview
Go deeper on NCT02480634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02480634.